Division of Nephrology Department of Internal Medicine Kyung Hee University Seoul Republic of Korea.
Division of Cardiology Department of Internal Medicine Kyung Hee University Seoul Republic of Korea.
J Am Heart Assoc. 2022 Jun 7;11(11):e024649. doi: 10.1161/JAHA.121.024649. Epub 2022 Jun 3.
Background Hydrophilic and lipophilic statins have similar efficacies in treating coronary artery disease. However, specific factors relevant to renal impairment and different arterial pathogeneses could modify the clinical effects of statin lipophilicity, and create differences in protective effects between statin types in patients with renal impairment. Methods and Results A total of 2062 patients with acute myocardial infarction with an estimated glomerular filtration rate <60 mL/min per 1.73 m were enrolled from the Korea Acute Myocardial Infarction Registry between November 2011 and December 2015. The primary end point was a composite of 2-year major adverse cardiac and cerebrovascular events (MACEs) after acute myocardial infarction occurrence. MACEs were defined as all-cause death, recurrent myocardial infarction, revascularization, and stroke. Propensity-score matching and Cox proportional hazards regression were performed. A total of 529 patients treated with hydrophilic statins were matched to 529 patients treated with lipophilic statins. There was no difference in the statin equivalent dose between the 2 statin groups. The cumulative event rate of MACEs, all-cause mortality, and recurrent myocardial infarction were significantly lower in patients treated with hydrophilic statins in the propensity-score matched population (all <0.05). In the multivariable Cox regression analysis, patients treated with hydrophilic statins had a lower risk for composite MACEs (hazard ratio [HR], 0.70 [95% CI, 0.55-0.90]), all-cause mortality (HR, 0.67 [95% CI, 0.49-0.93]), and recurrent myocardial infarction (HR, 0.40 [95% CI, 0.21-0.73]), but not for revascularization and ischemic stroke. Conclusions Hydrophilic statin treatment was associated with lower risk of MACEs and all-cause mortality than lipophilic statin in a propensity-score matched observational cohort of patients with renal impairment following acute myocardial infarction.
亲水性和疏水性他汀类药物在治疗冠状动脉疾病方面具有相似的疗效。然而,与肾功能损害和不同动脉发病机制相关的具体因素可能会改变他汀类药物疏水性的临床效果,并在肾功能损害患者中产生不同类型他汀类药物的保护作用差异。
2011 年 11 月至 2015 年 12 月,从韩国急性心肌梗死注册中心共纳入 2062 例估计肾小球滤过率<60 ml/min/1.73 m 的急性心肌梗死患者。主要终点是急性心肌梗死后 2 年主要不良心脑血管事件(MACEs)的复合终点。MACEs 定义为全因死亡、复发性心肌梗死、血运重建和中风。采用倾向评分匹配和 Cox 比例风险回归进行分析。将 529 例接受亲水性他汀类药物治疗的患者与 529 例接受疏水性他汀类药物治疗的患者进行匹配。两组他汀类药物等效剂量无差异。在倾向评分匹配人群中,亲水性他汀类药物治疗组的 MACEs、全因死亡率和复发性心肌梗死的累积事件发生率明显较低(均<0.05)。多变量 Cox 回归分析显示,亲水性他汀类药物治疗组的复合 MACEs(风险比[HR],0.70[95%CI,0.55-0.90])、全因死亡率(HR,0.67[95%CI,0.49-0.93])和复发性心肌梗死(HR,0.40[95%CI,0.21-0.73])风险较低,但血运重建和缺血性卒中等事件无差异。
在急性心肌梗死后肾功能损害的倾向评分匹配观察队列中,亲水性他汀类药物治疗与较低的 MACEs 和全因死亡率风险相关,而非疏水性他汀类药物。